CurrentmhnPolicy CP.MP.85

Neonatal Sepsis Management

Governs medical necessity and level-of-care management for neonates with suspected or proven sepsis, including criteria for nursery level placement, discharge, and peripartum maternal management; affects providers caring for newborns and birthing individuals in Health Plans affiliated with Centene Corporation.

Policy Summary

Payermhn

PolicyNeonatal Sepsis Management

Policy CodePolicy CP.MP.85

Change TypeNo material change

Effective Date

Next Review Date

Key ActionPlace symptomatic infants meeting sepsis criteria in level III nursery; well-appearing infants on 48 hours of antibiotics pending cultures may be managed in level II.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

36-48hrecommended antibiotic observation period

48hinitial antibiotic duration referenced

≤2dasymptomatic appropriate for Level II

Centenepolicy owner

Coverage and Medical Necessity Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Episode Day 1 - Well-appearing: Well-appearing infants who are on 48 hours of antibiotics pending blood culture results are appropriate for level II (rev code 172) nursery.48 hours

From I.A.1; see rev code 172

Episode Day 1 - Symptomatic: Symptomatic infants are appropriate for level III (rev code 173) nursery when ALL of the following are present: (a) signs of neonatal sepsis (e.g., hypotonia, lethargy, poor oral feeding, tachycardia, bradycardia, grunting, nasal flaring, cyanosis); (b) temperature ≥ 100.4 °F (≥ 38.0 °C) or ≤ 96.8 °F (≤ 36.0 °C); (c) on 48 hours of antibiotics pending blood culture results or receiving treatment for positive blood cultures.temperature thresholds; 48 hours

From I.A.2 and temperature thresholds

Episode Day 2+ - Negative cultures continuing antibiotics: Infants with negative cultures who are determined to require antibiotics beyond 48 hours may be appropriate for transitional care or level I nursery (rev code 171) once antibiotics are the only intervention necessitating continued stay and if outpatient antibiotics are inappropriate or unmanageable.>48 hours

From II.B.1; see rev code 171

Episode Day 2+ - Symptomatic: Symptomatic infants remain appropriate for level III (rev code 173) nursery when ALL of the following are present: (a) signs of neonatal sepsis (e.g., hypotonia, lethargy, poor oral feeding, tachycardia, bradycardia, grunting, nasal flaring, cyanosis); (b) temperature ≥ 100.4 °F (≥ 38.0 °C) or ≤ 96.8 °F (≤ 36.0 °C); (c) on 48 hours of antibiotics pending blood culture results or receiving treatment for positive blood cultures.temperature thresholds; 48 hours

From II.B.2

Asymptomatic on antibiotics: Asymptomatic infants on 48 hours of antibiotics pending blood culture results for ≤ two days are appropriate for Level II (rev code 172) nursery.≤ 2 days

From CLINICAL POLICY section 3

Asymptomatic with positive blood culture: Asymptomatic infants with a positive blood culture and no other indications are appropriate for transitional care; once culture and sensitivity results are known and the infant is medically stable, transition to a lower level of care for treatment completion if no other indications exist.post-culture

From CLINICAL POLICY section 3 and transitional care guidance

Discharge criteria

Discharge, with or without home antibiotics, is medically appropriate when ALL of the following apply:

Discharge criteria list: (A) Member/enrollee is clinically stable; (B) Home situation is assessed and deemed adequate; (C) Parent or caretaker is agreeable with the plan of care; (D) If going home with antibiotics, all of the following are met: 1) contractual agreement of care signed with a home infusion company experienced in neonatal IV therapy or short-term intramuscular therapy; 2) secure IV access is in place, if chosen; 3) contact information for the responsible physician and back-up health care facility is provided to family and home care agency prior to discharge; (E) Provider follow-up scheduled within 48 hours of discharge.48 hours follow-up

From II. Discharge criteria

Maternal intrapartum prophylaxis criteria

Maternal identification and intrapartum management that determine neonatal risk and need for prophylaxis:

GBS in urine or prior infant with GBS: Birthing individuals with Group B streptococcus (GBS) isolated in the urine during the current pregnancy or with a prior infant who had invasive GBS disease should receive intravenous intrapartum antibiotic prophylaxis; third trimester screening is not required in this population.pregnancy GBS urine or prior infant

From Background I.A

GBS UTI management: Birthing individuals with symptomatic or asymptomatic GBS urinary tract infection detected during pregnancy should be treated per current standards for UTI in pregnancy and should receive intrapartum antibiotic prophylaxis to prevent early-onset GBS disease.GBS UTI

From Background I.B

Routine screening and positive culture at labor: All other birthing individuals should be screened at 36 0/7 through 37 6/7 weeks gestation for vaginal and rectal GBS colonization; at the time of labor or ROM, intrapartum antibiotic prophylaxis should be given to those with positive vaginal-rectal cultures, including those undergoing cesarean delivery (prophylaxis is not required if cesarean delivery occurs before labor with intact membranes).36 0/7–37 6/7 weeks; ROM/labor culture positive

From Background I.C and I.D

When to give intrapartum antibiotics if screening unavailable: When screening results are not available at the time of labor/delivery, give intrapartum antibiotics to birthing individuals who present with substantial risk of preterm birth, preterm pre-labor rupture of membranes (PPROM), ROM ≥ 18 hours at term, or intrapartum temperature ≥ 100.4 °F (≥ 38.0 °C). If none of these risks are present but there is a history of prior GBS colonization, offering prophylaxis or discussing it via shared decision-making is reasonable.clinical risk factors

From CLINICAL POLICY E

Suspected intraamniotic infection: If intraamniotic infection is suspected, use broad-spectrum antibiotic therapy that covers polymicrobial infections as well as GBS rather than a GBS-specific prophylactic agent.

From CLINICAL POLICY F

Coverage of services described in this policy is subject to the terms, conditions, exclusions, and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy or contract of insurance) and to applicable state and federal requirements. The policy is a guide to medical necessity and does not itself guarantee payment; Health Plan-level administrative policies and procedures and contractual provisions govern prior authorization, claims submission, and benefit administration.

The clinical policy is effective as determined by the Health Plan; providers should follow Health Plan-level administrative requirements and recognize that the policy does not replace professional judgment or contractual obligations.

Provider Responsibilities, Prior Auth, and Transition Rules

Prior Authorization

Level-of-care placement requirements

Place infants at the appropriate level of care per the policy clinical criteria. Well-appearing infants on 48 hours of antibiotics pending blood culture results may be appropriate for Level II (rev code 172). Symptomatic infants meeting specified signs, temperature thresholds, and antibiotic treatment conditions are appropriate for Level III (rev code 173). Infants with negative cultures requiring antibiotics beyond 48 hours may be appropriate for transitional care or Level I (rev code 171) when antibiotics are the only ongoing intervention and outpatient antibiotics are inappropriate or unmanageable.

Level I (rev code 171): transitional care or well-infant nursery when only antibiotic therapy necessitates stay and outpatient antibiotics are not feasible.
Level II (rev code 172): well-appearing infants on ≤48 hours of antibiotics pending culture results; asymptomatic infants on ≤2 days of antibiotics.
Level III (rev code 173): symptomatic infants with signs of sepsis, temperature ≥100.4°F or ≤96.8°F, and receiving 48 hours of antibiotics pending cultures or treating positive cultures.

Denial Risk

Denial risk if level-of-care criteria not met

Failure to meet the stated level-of-care criteria may result in denial of coverage or determination that the current placement is inappropriate. Providers should document clinical findings and rationale for level-of-care decisions to support medical necessity determinations.

Document specific signs/symptoms, temperature readings, culture status, and duration of antibiotic therapy.
If criteria for Level III are not met for symptomatic infants, consider transition to lower level per policy and document justification.

Note

Coverage document constraints

Coverage decisions are subject to the terms, conditions, exclusions and limitations of the member's coverage documents and applicable state/federal requirements. This clinical policy is guidance for medical necessity determinations but does not guarantee payment.

Verify member benefits, evidence of coverage, certificate of coverage, and plan-level administrative policies prior to proceeding.
Administrative prior authorization processes and plan-specific requirements may apply.

Documentation Required

Discharge documentation and home antibiotic requirements

For discharge with or without home antibiotics, ensure all discharge and home infusion requirements are met and documented. Transitional care should be considered if safe home administration of IV antibiotics is not feasible.

Confirm member is clinically stable, home situation adequate, and caregiver agrees with plan of care.
If sending home with antibiotics, obtain contractual agreement with a home infusion company experienced in neonatal IV or short-term IM therapy.
Ensure secure IV access if chosen and provide contact information for the responsible physician and back-up facility to family and home care agency prior to discharge.
Schedule provider follow-up within 48 hours of discharge.

Note

Transition to lower level once antibiotics are sole intervention

Once culture and sensitivity results allow establishment of targeted antibiotic therapy and the infant is medically stable with no other indications for the current level of care, transition the infant to a lower level of care for completion of treatment. Consider transitional care nursery if IV antibiotics cannot be safely administered at home.

Document culture results, antibiotic plan, and clinical stability to support step-down.
If home administration is unsafe or unmanageable, arrange transitional care rather than discharge home.

Clinical Background and Rationale

Group B Streptococcus (GBS) is identified as a principal contributor to early-onset neonatal sepsis, which occurs in the first six days of life; late-onset disease is defined separately beyond that period. Identification of maternal GBS colonization or infection during pregnancy (for example, GBS isolated in urine or a prior infant with invasive GBS) prompts intrapatrum IV antibiotic prophylaxis, which reduces the risk of early-onset disease. Neonatal management after birth depends on clinical status and gestational age and commonly includes blood cultures, empiric antibiotics, and observation; for ruling out sepsis due to perinatal risk factors, 36–48 hours of antibiotics pending culture results is considered appropriate, and sterile cultures generally support discontinuation of antibiotics by 36–48 hours unless site-specific infection is evident.

Key Definitions

GBS early-onset disease

DefinitionBlood or cerebrospinal fluid culture–proven infection occurring within the first six days of life.

Primary pathogen notedGroup B Streptococcus (GBS) is the leading cause of early-onset neonatal sepsis.

Clinical implicationEarly-onset GBS requires comprehensive assessment and timely treatment to reduce morbidity and mortality.

GBS late-onset disease

DefinitionIsolation of GBS from a normally sterile site from 7 to 89 days of age.

Relationship to early-onset diseaseGBS is also a major cause of late-onset sepsis; vigilance for sepsis signs remains important beyond the neonatal period.

Time windowOnset defined as days 7 through 89 of life.